|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.37/-2.04
|
企业价值
403.70M
|
资产负债 |
每股账面净值
1.07
|
现金流量 |
现金流量率
--
|
损益表 |
收益
64.70M
|
每股收益
1.62
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 12:51 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline ofautologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |